RxDoctor Payments Data

Samar Novak, APRN

Nurse Practitioner · Fayetteville, ARNPI 1114558996

Payments from drug & device makers

$2,557in general payments, 2019–2025

Across 150 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$529
  • Medtronic$488
  • Novartis$289
  • Amgen$196
  • Penumbra, Inc.$142
  • Novo Nordisk$139
  • plus $774 from 15 others

What the payments were for

  • Food & beverage$2,557100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,557 in reported general payments places this provider in the 85th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$58,947
Medicare patients
423
Services billed
746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$214,262
EntrestoSacubitril/Valsartan147$122,905
XareltoRivaroxaban58$48,980
BrilintaTicagrelor47$31,736
JardianceEmpagliflozin26$31,717
FarxigaDapagliflozin Propanediol35$21,103
Repatha SureclickEvolocumab17$17,481
Repatha SyringeEvolocumab19$14,798
Dofetilide15$6,218
Metoprolol Succinate297$5,014
Ranolazine ErRanolazine63$3,241
Atorvastatin Calcium313$2,729
Diltiazem 24hr Er (Cd)Diltiazem Hcl123$2,560
Nebivolol Hcl27$1,933
ClopidogrelClopidogrel Bisulfate182$1,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$529$214,262239 claims
NovartisEntresto$289$122,905147 claims
AstraZenecaBrilinta, Farxiga$119$52,83982 claims
Johnson & JohnsonXarelto$45$48,98058 claims
Boehringer IngelheimJardiance$33$31,71726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →